ESMO 2023

An analysis of Lifileucel's R&D progress and its clinical results presented at the 2023 ESMO_IO Annual Meeting

13 January 2024
4 min read

The large proportion of patients (pts) with advanced (unresectable or metastatic) melanoma resistant to immune checkpoint inhibitors (ICI) define a significant unmet need. Lifileucel, a one-time autologous TIL cell therapy, has demonstrated durable clinical benefit in this setting, with the C-144-01 study showing an ORR of 31.4% in a heavily pre-treated population. And the latest 4-year follow-up data from C-144-01 on lifileucel’s treatment outcomes and patterns of response were reported in 2023 ESMO_IO.

Lifileucel's R&D Progress

Lifileucel is a drug classified as TIL therapy, which stands for tumor-infiltrating lymphocyte therapy. It is primarily used in the treatment of various neoplasms, skin and musculoskeletal diseases, urogenital diseases, and eye diseases. The active indications for Lifileucel include melanoma, metastatic melanoma, unresectable melanoma, uterine cervical cancer, and uveal melanoma. 

图形用户界面, 应用程序

描述已自动生成

According to the Patsnap Synapse, Lifileucel was developed by the National Institutes of Health (NIH), a renowned organization in the field of biomedical research. Lifileucel has reached the highest phase of development, which is the New Drug Application (NDA) or Biologics License Application (BLA) stage. And the clinical trial distributions for Lifileucel are primarily in the United States, United Kingdom and France. The key indication is Metastatic melanoma

表格

描述已自动生成

Detailed Clinical Result of Lifileucel

This non-randomized, parallel assignment, open-labeled clinical trial (NCT02360579) was aimed to explore the long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma. 

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

In this study, pts had ≥1 lesion(s) resected (≥1.5 cm diameter) for 22-day cryopreserved lifileucel manufacturing. The treatment regimen consisted of nonmyeloablative lymphodepletion (cyclophosphamide 60 mg/kg/d × 2d, fludarabine 25 mg/m2/d × 5d), followed by a single lifileucel infusion and ≤6 doses of high-dose IL-2 (600,000 IU/kg).

表格

描述已自动生成

The result showed that as of data cutoff (30 June 2023), 153 pts were assessed; median study follow-up was 48.1 months. Independent review committee-assessed ORR by RECIST v1.1 was 31.4% with median DOR (months) of NR. The 1-, 2-, 3-, and 4-year OS rate was 54.0%, 33.9%, 28.4%, and 21.9%, respectively. Responders (n=48) had a median age of 55.0 years with median of 3 prior lines of therapies. Clinically meaningful 4-year OS rates were seen across all patterns of response (range, 37.2%–68.2%); pts with deepened response had numerically higher OS rate. Treatment-emergent adverse events were consistent with known safety profiles of lymphodepletion and IL-2.

It can be concluded that in this 4-year analysis of heavily pretreated pts with advanced melanoma, treatment with lifileucel produced durable efficacy, leading to long-term survival benefit across different patterns of responders.

How to Easily View the Clinical Results Using Synapse Database?

If you want to know the other clinical results of popular conferences, please lick on the “Clinical Results” on the homepage of Patsnap Synapse, which provides multi-dimensional screening and filtering of drugs, indications, targets, companies, result evaluation, release date, popular conferences, etc. to help you quickly locate the data you need. 

Select the clinical meeting you are interested in, such as ESMO. In the results, you can quickly locate the data you want to view by indication, phase and drug name. 

图形用户界面, 文本, 应用程序

描述已自动生成

A single result clearly shows important information such as registration number, phase, indication, Sponsor/Collaborator, biomarker, Trial number, dosing regimen and more. 

图形用户界面, 文本, 应用程序

描述已自动生成

If you would like to view more information about this result, you can go to the result detail page by clicking on the title. 

Above the headings, we provide the original source of the outcome data. The basic information is supplemented with more information beyond the list, such as company, study. design, etc. 

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

In the important Outcome Measures section, we provide both list and flowchart forms, which are convenient for you to overview the comparison group information and core indicator data. 

表格

描述已自动生成

表格

描述已自动生成

Finally, if you need to download these results, you can conveniently check the check boxes on the left side of the list, or directly click the "Export" button to download the data for personalized analysis and file sharing.

Click on the image below to embark on a brand new journey of drug discovery!

Sana Biotech's SC262, a CD22-targeted CAR T cell therapy for resistant B-cell cancers, gains US regulatory approval
Latest Hotspot
3 min read
Sana Biotech's SC262, a CD22-targeted CAR T cell therapy for resistant B-cell cancers, gains US regulatory approval
13 January 2024
Sana Biotech Reveals US Regulatory Approval for Experimental Drug SC262, an Engineered Immune-resistant, Targeted CD22 Allo CAR T Cell Treatment, Aimed at Individuals Suffering from Recurring or Resistant Types of B-cell Cancer.
Read →
Where should clinical trial documents be kept?
Knowledge Base
2 min read
Where should clinical trial documents be kept?
13 January 2024
There are no explicit provisions on the storage of test related documents. However, ichgcp stipulates the minimum filing documents - basic documents.
Read →
Boston Pharma Debuts BOS-580 Study at 2024 NASH-TAG, Highlights Lasting Low Immune Response for MASH Treatment
Latest Hotspot
3 min read
Boston Pharma Debuts BOS-580 Study at 2024 NASH-TAG, Highlights Lasting Low Immune Response for MASH Treatment
10 January 2024
Boston Pharmaceuticals Unveils Research at the 2024 NASH-TAG Showing Sustained Low Immune Reaction to their Extended-release FGF21 Mimic, BOS-580, in MASH Management.
Read →
What are FXR agonists and how do you quickly get the latest development progress?
What are FXR agonists and how do you quickly get the latest development progress?
10 January 2024
FXR agonists are drugs that activate the farnesoid X receptor, regulating bile acid synthesis and aiding in the treatment of liver and metabolic disorders.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.